Drugs / Rabies Human Immunoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06548139 Comparator | Jul 2024 → May 2025 overdue | rabies | Changchun BCHT Biotechnology Co. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rabies Human Immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06548139 ↗ |
| Known as | HRIG | “Rabies Human Immunoglobulin (HRIG)” NCT06548139 ↗ |
| Modality | Protein / enzyme biologic | “Active ingredient: Rabid human immunoglobulin” NCT06548139 ↗ |
| Route | Intramuscular | “Administration mode: intramuscular injection of the vastus lateral muscle group.” NCT06548139 ↗ |